<DOC>
	<DOCNO>NCT00774683</DOCNO>
	<brief_summary>The purpose research sub-study learn level antiretroviral ( ARV ) medication call Raltegravir , response HIV virus genital tract HIV-positive woman . We would like see study medication tolerate , body process study medication woman HIV-positive . More specifically , interested Isentress® might penetrate female cervicovaginal secretion thereby potentially reduce amount HIV secretion . A reduction amount HIV genital secretion may prevent female subject transmit HIV sexual partner . This information help research team know medication Isentress® might use prevent sexual transmission HIV .</brief_summary>
	<brief_title>A Pilot Study Characterize Pharmacokinetics Raltegravir Cervicovaginal Fluids HIV-infected Women</brief_title>
	<detailed_description>Purpose : This study aim characterize pharmacokinetics raltegravir cervicovaginal fluid HIV-infected woman , compare blood plasma pharmacokinetics obtain main study , CID 0706 . Participants : Six HIV-positive woman CID 0706 study Procedures : During pharmacokinetic visit obtain blood plasma CID 0706 study , woman ask self-collect cervicovaginal sample use vaginal aspirator follow timepoints : pre-dose 1 , 2 , 4 , 6 , 8 , 12 hour raltegravir 400mg dose administration .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1 infection document HIV serology detectable viral load Selfdescribed AfricanAmerican Less 7 day cumulative prior HIV therapy Plasma HIV RNA PCR equal great 1000 copies/mL within 90 day prior study entry Able provide inform consent In opinion investigator , able comply study medication procedure ALT ( SGPT ) &lt; equal 3.0 x ULN within 45 day prior study entry GRF &gt; 60 calculated MDRD within 45 day prior study entry All woman reproductive potential ( reach menopause undergone hysterectomy , bilateral oophorectomy , tubal ligation ) must negative serum urine βHCG pregnancy test perform within 48 hour entry . All study volunteer must agree participate conception process ( e.g. , active attempt become pregnant impregnate , sperm donation , vitro fertilization ) , participate sexual activity could lead pregnancy , female study volunteer/male partner must use least one reliable method contraception ( e.g. , condom , without spermicidal agent ; diaphragm cervical cap spermicide ; IUD ; hormonalbased contraception ) , simultaneously receive protocolspecified medication ( ) 6 week stop medication ( ) . Pregnancy Breastfeeding Prior receipt Raltegravir Any condition opinion investigator likely interfere followup ability take study medication appropriately A positive test bacterial vaginosis , syphilis , gonorrhea , Chlamydia , HSV2 ( active lesion ) , trichomonas entry week 2 main study , CID 0706</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Pilot</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Cervicovaginal</keyword>
	<keyword>HIV</keyword>
	<keyword>Women</keyword>
</DOC>